ProMetic Life Sciences Inc. (TSE:PLI – Get Free Report) traded up 0.2% during trading on Monday . The stock traded as high as C$13.72 and last traded at C$13.60. 921 shares were traded during trading, a decline of 88% from the average session volume of 8,002 shares. The stock had previously closed at C$13.57.
ProMetic Life Sciences Price Performance
The stock has a market capitalization of C$317.06 million and a P/E ratio of -0.22. The company has a debt-to-equity ratio of 37.47, a quick ratio of 3.66 and a current ratio of 4.06. The stock’s 50-day moving average is C$13.60.
ProMetic Life Sciences Company Profile
Prometic Life Sciences Inc operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals.
See Also
- Five stocks we like better than ProMetic Life Sciences
- Insider Trading – What You Need to Know
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- Roth IRA Calculator: Calculate Your Potential Returns
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- Investing in Commodities: What Are They? How to Invest in Them
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for ProMetic Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
